Figure 2From: Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial Patient disposition. (A) Safety/PK component. (B) Proof-of-concept component. *Discontinued because the study was terminated by the sponsor. AE, adverse event; BID, twice daily; LOE, lack of efficacy; NLW, no longer willing (to participate in study).Back to article page